Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells

Background. Human immunodeficiency virus type 1 (HIV-1) populations are detected in cerebrospinal fluid (CSF) of some people on suppressive antiretroviral therapy (ART). Detailed analysis of these populations may reveal whether they are produced by central nervous system (CNS) reservoirs. Methods. We performed a study of 101 asymptomatic participants on stable ART. HIV-1 RNA concentrations were cross-sec-tionally measured in CSF and plasma. In participants with CSF HIV-1 RNA concentrations sufficient for analysis, viral populations were genetically and phenotypically characterized over multiple time points. Results. For 6% of participants (6 of 101), the concentration of HIV-1 RNA in their CSF was ≥ 0.5 log copies/mL above that of plasma (ie, CSF escape). We generated viral envelope sequences from CSF of 3 participants. One had a persistent CSF escape population that was macrophage-tropic, partially drug resistant, genetically diverse, and closely related to a minor macrophage-tropic lineage present in the blood prior to viral suppression and enriched for after ART. Two participants (1 suppressed and 1 not) had transient CSF escape populations that were R5 T cell-tropic with little genetic diversity. Conclusions. Extensive analysis of viral populations in 1 participant revealed that CSF escape was from a persistently replicating population, likely in macrophages/microglia, present in the CNS over 3 years of ART. CSF escape in 2 other participants was likely produced by trafficking and transient expansion of infected T cells in the CNS. Our results show that CNS reservoirs can persist during ART and that CSF escape is not exclusively produced by replicating CNS reservoirs.

[1]  R. Swanstrom,et al.  The evolution of HIV‐1 entry phenotypes as a guide to changing target cells , 2018, Journal of leukocyte biology.

[2]  G. di Perri,et al.  Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia , 2018, Journal of NeuroVirology.

[3]  J. Mellors,et al.  No evidence of HIV replication in children on antiretroviral therapy. , 2017, The Journal of clinical investigation.

[4]  J. Lifson,et al.  Defining total-body AIDS-virus burden with implications for curative strategies , 2017, Nature Medicine.

[5]  Ellen R. Forsyth,et al.  Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir , 2017, mBio.

[6]  G. Fogel,et al.  HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads , 2016, Journal of Virology.

[7]  C. Leen,et al.  Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia , 2016, Journal of NeuroVirology.

[8]  Nancie M Archin,et al.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.

[9]  William D. Graham,et al.  Phenotypic Correlates of HIV-1 Macrophage Tropism , 2015, Journal of Virology.

[10]  P. Mieczkowski,et al.  Primer ID Validates Template Sampling Depth and Greatly Reduces the Error Rate of Next-Generation Sequencing of HIV-1 Genomic RNA Populations , 2015, Journal of Virology.

[11]  R. Price,et al.  Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy , 2015, Current HIV/AIDS Reports.

[12]  R. Swanstrom,et al.  Affinofile Assay for Identifying Macrophage-Tropic HIV-1. , 2014, Bio-protocol.

[13]  J. Mellors,et al.  Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[14]  J. Hoxie,et al.  Quantification of Entry Phenotypes of Macrophage-Tropic HIV-1 across a Wide Range of CD4 Densities , 2013, Journal of Virology.

[15]  E. L. Potter,et al.  Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design , 2013, Journal of Virology.

[16]  M. Peluso,et al.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load , 2012, AIDS.

[17]  P. Kubes,et al.  Immune surveillance in the central nervous system , 2012, Nature Neuroscience.

[18]  A. Phillips,et al.  Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Price,et al.  Antiretroviral drug treatment of CNS HIV-1 infection. , 2012, The Journal of antimicrobial chemotherapy.

[20]  R. Swanstrom,et al.  HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types , 2011, PLoS pathogens.

[21]  J. Clements,et al.  A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system , 2011, Current opinion in HIV and AIDS.

[22]  D. Fuchs,et al.  HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. , 2010, The Journal of infectious diseases.

[23]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[24]  D. Burton,et al.  Determinants Flanking the CD4 Binding Loop Modulate Macrophage Tropism of Human Immunodeficiency Virus Type 1 R5 Envelopes , 2009, Journal of Virology.

[25]  Joseph A Kovacs,et al.  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.

[26]  Steven Wolinsky,et al.  The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia , 2006, Proceedings of the National Academy of Sciences.

[27]  P. Simmonds,et al.  Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis , 2006, Journal of Virology.

[28]  W. Cao,et al.  HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. , 2006, Virology.

[29]  R. Tidwell,et al.  High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[30]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[31]  John P. Moore,et al.  Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate , 2002, Journal of Virology.

[32]  W. Heneine,et al.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.